Project Grant HT94252310286
Award Date
4/15/23
Completion Date
4/14/25
Dollars Obligated
$778K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $796,875 project grant to the University of Florida (UF) Division of Sponsored Research. The grant, awarded on April 1, 2024, supports the development of heterobifunctional degraders of TDP-43 as a novel therapeutic strategy for amyotrophic lateral sclerosis (ALS). Under this grant, the University of North Carolina at Chapel Hill (UNC-CH) Office of Sponsored Research is serving as a sub-awardee....
The University of Denver was awarded a $877,397 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "SYNTHETIC PROTEIN MIMETICS-BASED SPECIFIC TARGETING AND DEGRADATION OF TDP-43 AGGREGATION ASSOCIATED WITH ALS". This 2-year grant, with an award date of March 1, 2024 and a completion date of February 28, 2026, will support the university's research efforts to develop new treatments for amyotrophic...
The University of North Carolina at Chapel Hill (UNC-CH) was awarded a $489,065 Project Grant from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, awarded on July 1, 2025, supports research to develop "Potentiated Chip Variants as Therapeutics to Alleviate Tau Pathology and Neurodegeneration". The program funds advanced biomedical research focused on transforming healthcare for military service members and...
The Defense Health Agency awarded a $929,948 Project Grant to The Washington University in St. Louis, Missouri to support the research project "TARGETING TDP-43 MITOCHONDRIAL MISLOCALIZATION IN ALS". This grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research aimed at improving the health and care of military service members, veterans, and their families. The research project will investigate mitochondrial...
The University of North Carolina at Chapel Hill was awarded a $1,200,470 project grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research into pathogenic T cells in Guillain-Barré syndrome from September 30, 2021 through September 29, 2025. As part of the Military Medical Research and Development program's goals of transforming military and public health through innovative medical research and...
The Trustees of Columbia University in New York City will receive $486,000 from the Defense Health Agency through March 2024 to analyze the adaptive and innate immune response in patients with amyotrophic lateral sclerosis (ALS) who have been treated with antisense oligonucleotides. This Project Grant was awarded on April 1, 2021 under the Military Medical Research and Development program (CFDA 12.420). The Defense Health Agency's Military Medical Research and Development program aims to...
The Johns Hopkins University was awarded a $1,623,356 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from August 1, 2023 to July 31, 2026 to develop CHMP7 antisense oligonucleotide (ASO) therapy to repair nuclear pore and TDP43 dysfunction in sporadic and familial forms of amyotrophic lateral sclerosis (ALS). The Military Medical Research and Development program supports basic, applied, and...
This Project Grant award of $798,272.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports research at The Johns Hopkins University to test the use of Wnt inhibitors as a potential therapeutic approach to reverse TDP-43 dysfunction in amyotrophic lateral sclerosis (ALS). The research project will be conducted over a 2-year period from March 2025 to March 2027, with the goal of advancing...
The Defense Health Agency awarded a $1.19 million Project Grant to The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. from May 1, 2023 to April 30, 2026 under the Military Medical Research and Development program (CFDA 12.420). The grant funds research into targeting excessive sphingolipid synthesis for treatment of amyotrophic lateral sclerosis (ALS) being conducted by Dr. Teresa M. Dunn of the Uniformed Services University of the Health Sciences. Dr. Dunn is...
The University of Massachusetts Medical School has been awarded a $987,615 federal Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, which runs from September 30, 2024 to September 29, 2026, supports the "Development of Chimeric Antigen Receptor T Regulatory Cells (CAR Tregs) for the Treatment of Amyotrophic Lateral Sclerosis." This project aims to advance research into new therapeutic approaches for...